{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:09:19Z","timestamp":1779260959230,"version":"3.51.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Empagliflozin and sitagliptin are commonly co-administered to manage type 2 diabetes mellitus due to their complementary mechanisms of action on renal glucose reabsorption and insulin secretion, respectively. This synergistic effect enhances glycemic control with a minimal risk of hypoglycemia. In this study, a sensitive, simple, rapid, and selective spectrofluorimetric method was developed for the simultaneous determination of empagliflozin in the presence of sitagliptin in pharmaceutical formulations and spiked human plasma. Both drugs exhibit native fluorescence; however, their emission spectra significantly overlap, complicating their simultaneous analysis with conventional spectrofluorimetric techniques. To overcome this limitation, second-derivative synchronous spectrofluorimetry was applied. Measurements were performed within an optimized wavelength interval (\u0394\u03bb\u2009=\u200960\u00a0nm), enabling selective determination of sitagliptin at 393\u00a0nm and empagliflozin at 310\u00a0nm without mutual interference. Experimental parameters affecting fluorescence intensity, including solvent type, pH, and \u0394\u03bb, were carefully optimized to achieve maximum sensitivity and selectivity. The proposed method demonstrated excellent analytical performance, with limits of detection of 0.031\u00a0\u00b5g\/mL and 0.011\u00a0\u00b5g\/mL, and limits of quantification of 0.093\u00a0\u00b5g\/mL and 0.033\u00a0\u00b5g\/mL for sitagliptin and empagliflozin, respectively. Good linearity was observed over concentration ranges of 0.1\u20134\u00a0\u00b5g\/mL for sitagliptin and 0.04\u20131.2\u00a0\u00b5g\/mL for empagliflozin. The method was successfully applied to spiked human plasma samples and validated in accordance with ICH guidelines, demonstrating satisfactory accuracy, precision, robustness, and selectivity. A statistical comparison with a reported method showed no significant difference in performance. The environmental sustainability of the proposed method was comprehensively evaluated using several green analytical chemistry assessment tools, including the Carbon Footprint Reduction Index (CaFRI), Eco-Scale, AGREEprep, CompMoGAPI, and NEMI. In addition, the Blue Applicability Grade Index (BAGI) was employed to assess the method\u2019s blueness, reflecting its practical applicability. Furthermore, the RGB 12 algorithm was applied to evaluate the method\u2019s overall whiteness by integrating its environmental impact (greenness), analytical performance (redness), and practical efficiency (blueness). The obtained results consistently confirmed the excellent eco-friendly profile of the proposed method, demonstrating minimal environmental impact, reduced solvent consumption, strong compliance with green analytical chemistry principles, and high overall performance.<\/jats:p>","DOI":"10.1038\/s41598-026-53178-z","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:53:20Z","timestamp":1779256400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples"],"prefix":"10.1038","volume":"16","author":[{"given":"Ahmad A. A.","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Almrasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed H.","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S.","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"2","key":"53178_CR1","first-page":"V","volume":"1","author":"SAJI Tabish","year":"2007","unstructured":"Tabish, S. A. J. I. Is diabetes becoming the biggest epidemic of the twenty-first century?. Int. J. Health Sci 1(2), V (2007).","journal-title":"Int. J. Health Sci"},{"issue":"10","key":"53178_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrendo.2016.105","volume":"12","author":"P Zimmet","year":"2016","unstructured":"Zimmet, P., Alberti, K. G., Magliano, D. J. & Bennett, P. H. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies. J. Nat. Rev. Endocrinol. 12(10), 616\u2013622. https:\/\/doi.org\/10.1038\/nrendo.2016.105 (2016).","journal-title":"J. Nat. Rev. Endocrinol."},{"key":"53178_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-1542-7","volume-title":"Diabetes mellitus in 21st century","author":"S Sen","year":"2016","unstructured":"Sen, S., Chakraborty, R. & De, B. Diabetes mellitus in 21st century (Springer, 2016)."},{"issue":"7","key":"53178_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole, J. B. & Florez, J. C. Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol. 16(7), 377\u2013390. https:\/\/doi.org\/10.1038\/s41581-020-0278-5 (2020).","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"53178_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic, D., Shaw, J. E. & Magliano, D. J. The burden and risks of emerging complications of diabetes mellitus. J. Nat. Rev. Endocrinol. 18 (9), 525\u2013539. https:\/\/doi.org\/10.1038\/s41574-022-00690-7 (2022).","journal-title":"J. Nat. Rev. Endocrinol."},{"issue":"2","key":"53178_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","volume":"100","author":"E Gronda","year":"2022","unstructured":"Gronda, E. et al. Pharmacology. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Can. J. Physiol. Pharmacol. 100 (2), 93\u2013106. https:\/\/doi.org\/10.1139\/cjpp-2021-0399 (2022).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"53178_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10741-021-10079-9","volume":"27","author":"M Nikolic","year":"2022","unstructured":"Nikolic, M. et al. SGLT2 inhibitors: A focus on cardiac benefits and potential mechanisms. Heart Fail Rev 27, 935\u2013949. https:\/\/doi.org\/10.1007\/s10741-021-10079-9 (2022).","journal-title":"Heart Fail Rev"},{"issue":"10","key":"53178_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma, S. & McMurray, J. J. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. J. Diabetologia 61(10), 2108\u20132117. https:\/\/doi.org\/10.1007\/s00125-018-4670-7 (2018).","journal-title":"J. Diabetologia"},{"issue":"11","key":"53178_CR9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","volume":"60","author":"AJ Barnett","year":"2006","unstructured":"Barnett, A. J. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60(11), 1454\u20131470. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01178.x (2006).","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"53178_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill, E. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. J. Endocr. Rev. 35 (6), 992\u20131019. https:\/\/doi.org\/10.1210\/er.2014-1035 (2014).","journal-title":"J. Endocr. Rev."},{"issue":"1","key":"53178_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5958\/2231-5675.2017.00004.7","volume":"7","author":"SD Patil","year":"2017","unstructured":"Patil, S. D., Chaure, S. K., Rahman, M. A. H., Varpe, P. U. & Kshirsagar, S. J. A. Development and validation of simple UV-spectrophotometric method for the determination of empagliflozin. Asian J. Pharm. Anal. 7(1), 18\u201322. https:\/\/doi.org\/10.5958\/2231-5675.2017.00004.7 (2017).","journal-title":"Asian J. Pharm. Anal."},{"issue":"2","key":"53178_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10812-024-01734-8","volume":"91","author":"S Sahu","year":"2024","unstructured":"Sahu, S., Pandey, R. K., Shukla, S. S. & Gidwani, B. J. Spectrophotometric method development and validation of empagliflozin in active pharmaceutical ingredient and tablet dosage form. J. Appl. Spectrosc. 91(2), 405\u2013410. https:\/\/doi.org\/10.1007\/s10812-024-01734-8 (2024).","journal-title":"J. Appl. Spectrosc."},{"key":"53178_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2020.118307","volume":"235","author":"MA Omar","year":"2020","unstructured":"Omar, M. A., Ahmed, H. M., Batakoushy, H. A. & Hamid, M. A. A. New spectrofluorimetric analysis of empagliflozin in its tablets and human plasma using two level full factorial design. J. Spectrochim. Acta A Mol. Biomol. Spectrosc 235, 118307. https:\/\/doi.org\/10.1016\/j.saa.2020.118307 (2020).","journal-title":"J. Spectrochim. Acta A Mol. Biomol. Spectrosc"},{"issue":"7","key":"53178_CR14","first-page":"28","volume":"5","author":"FM Salama","year":"2018","unstructured":"Salama, F. M., Attia, K. A., Abouserie, A. A., Mabrouk, R. A. & Abdelzaher, A. M. Spectrofluorimetric estimation of empagliflozin in the presence of its oxidative degradation product. EJBPS 5(7), 28\u201333 (2018).","journal-title":"EJBPS"},{"issue":"5","key":"53178_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/bio.3491","volume":"33","author":"MF Abdel-Ghany","year":"2018","unstructured":"Abdel-Ghany, M. F., Ayad, M. F. & Tadros, M. M. Liquid chromatographic and spectrofluorimetric assays of empagliflozin: Applied to degradation kinetic study and content uniformity testing. Luminescence 33(5), 919\u2013932. https:\/\/doi.org\/10.1002\/bio.3491 (2018).","journal-title":"Luminescence"},{"key":"53178_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9983477","volume":"1","author":"B Ayoub","year":"2021","unstructured":"Ayoub, B., El Zahar, N., Michel, H. & Tadros, M. J. Economic spectrofluorometric bioanalysis of empagliflozin in rats\u2019 plasma. J.Anal. Methods Chem 1, 9983477. https:\/\/doi.org\/10.1155\/2021\/9983477 (2021).","journal-title":"J.Anal. Methods Chem"},{"issue":"10","key":"53178_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/bio.4917","volume":"39","author":"DH Rushdy","year":"2024","unstructured":"Rushdy, D. H., Atia, N. N., Ali, M. F. & El-Gizawy, S. M. A highly sensitive inclusion complex based spectrofluorimetric method for the determination of certain Sodium Glucose Cotransporter\u20102 Inhibitors: Greenness assessment and application to different biological fluids. Luminescence 39(10), e4917. https:\/\/doi.org\/10.1002\/bio.4917 (2024).","journal-title":"Luminescence"},{"issue":"8","key":"53178_CR18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/bio.4526","volume":"38","author":"NM Hosny","year":"2023","unstructured":"Hosny, N. M., GadAllah, M. I. & Qayed, W. S. Combined experimental\/computational aspects for the molecular interaction of empagliflozin with bovine serum albumin: Quantification and application to human plasma. J. Lumin. 38(8), 1449\u20131457. https:\/\/doi.org\/10.1002\/bio.4526 (2023).","journal-title":"J. Lumin."},{"key":"53178_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2023.122715","volume":"296","author":"IM Nour","year":"2023","unstructured":"Nour, I. M., Mohamed, A. R., Hasan, M. A. & Badrawy, M. Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: docking simulation. Spectrochim. Acta A Mol. Biomol. Spectrosc. 296, 122715. https:\/\/doi.org\/10.1016\/j.saa.2023.122715 (2023).","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"53178_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2020.119258","volume":"248","author":"MS Elmasry","year":"2021","unstructured":"Elmasry, M. S., Hasan, M. A., Hassan, W. S., Merey, H. A. & Nour, I. M. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma. Spectrochim. Acta A Mol. Biomol. Spectrosc. 248, 119258. https:\/\/doi.org\/10.1016\/j.saa.2020.119258 (2021).","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"5","key":"53178_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.22159\/ijap.2019vv11i5.33281","volume":"11","author":"M Basak","year":"2019","unstructured":"Basak, M., Gouru, S. R., Bera, A. & Nagappan, K. V. J. I. A rapid and sensitive RP-HPLC method for the quantitative analysis of empagliflozin in bulk and pharmaceutical dosage form. Int. J. Appl. Pharm. 11(5), 60\u201365. https:\/\/doi.org\/10.22159\/ijap.2019vv11i5.33281 (2019v).","journal-title":"Int. J. Appl. Pharm."},{"issue":"6","key":"53178_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/chromsci\/bmaa129","volume":"59","author":"SL Burin","year":"2021","unstructured":"Burin, S. L. et al. Development of an HPLC-UV method to assay Empagliflozin tablets and identification of the major photoproduct by quadrupole time-of-flight mass spectrometry. J. Chromatogr. Sci. 59(6), 526\u2013535. https:\/\/doi.org\/10.1093\/chromsci\/bmaa129 (2021).","journal-title":"J. Chromatogr. Sci."},{"issue":"23B","key":"53178_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.9734\/jpri\/2022\/v34i23B35926","volume":"34","author":"AV Gaikwad","year":"2022","unstructured":"Gaikwad, A. V. & Khulbe, P. J. HPLC method development for the estimation of Empagliflozin in bulk and pharmaceutical formulation. J. Pharm. Res. Int. 34(23B), 22\u201331 (2022).","journal-title":"J. Pharm. Res. Int."},{"issue":"3","key":"53178_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.36721\/PJPS.2021.34.3.SUP.1081-1087.1","volume":"34","author":"AM Hanif","year":"2021","unstructured":"Hanif, A. M. et al. HPLC based analytical method development and application to pharmaceutical raw material and dosage form. J. Med. Sci. 34 (3), 1081\u20131087. https:\/\/doi.org\/10.36721\/PJPS.2021.34.3.SUP.1081-1087.1 (2021).","journal-title":"J. Med. Sci."},{"issue":"1","key":"53178_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-021-00329-w","volume":"7","author":"S Pathak","year":"2021","unstructured":"Pathak, S. & Mishra, P. J. F. Stability-indicating HPLC-DAD method for the determination of Empagliflozin. Future J. Pharm. Sci. 7(1), 181. https:\/\/doi.org\/10.1186\/s43094-021-00329-w (2021).","journal-title":"Future J. Pharm. Sci."},{"issue":"10","key":"53178_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/separations9100275","volume":"9","author":"EY Santali","year":"2022","unstructured":"Santali, E. Y. et al. Greenness assessment of chromatographic methods used for analysis of Empagliflozin: A comparative study. Separations 9(10), 275. https:\/\/doi.org\/10.3390\/separations9100275 (2022).","journal-title":"Separations"},{"issue":"1","key":"53178_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21276\/ijpbs.2019.9.1.4","volume":"9","author":"V Shirisha","year":"2019","unstructured":"Shirisha, V., Bolle, K., Santosh, I., Rao, K. & Rajeswar, D. J. I. A new simple method development, validation and forced degradation studies of Empagliflozin by using Rp-Hplc. Int. J. Pharm. Biol. Sci. 9(1), 25\u201335. https:\/\/doi.org\/10.21276\/ijpbs.2019.9.1.4 (2019).","journal-title":"Int. J. Pharm. Biol. Sci."},{"issue":"7","key":"53178_CR28","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.20959\/wjpr20177-8741","volume":"6","author":"SH Jaiswal","year":"2017","unstructured":"Jaiswal, S. H., Katariya, M., Katariya, V., Karva, G. & Koshe, K. J. W. Validated stability indicating HPLC method for determination of process related impurities in Empagliflozin drug substances. World J. Pharm. Res. 6(7), 1025\u20131037. https:\/\/doi.org\/10.20959\/wjpr20177-8741 (2017).","journal-title":"World J. Pharm. Res."},{"key":"53178_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.112730","volume":"209","author":"NF El Azab","year":"2025","unstructured":"El Azab, N. F., Alqirsh, S. M., Magdy, N. & Abdel-Ghany, M. F. Enhanced sensitivity in Empagliflozin detection: A voltammetric sensor with molecularly imprinted graphite film for analyzing pharmaceuticals and biological fluids. Microchem. J. 209, 112730. https:\/\/doi.org\/10.1016\/j.microc.2025.112730 (2025).","journal-title":"Microchem. J."},{"issue":"6","key":"53178_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/22297928.2018.1545603","volume":"8","author":"RM Ahmed","year":"2018","unstructured":"Ahmed, R. M., Hadad, G. M., El-Gendy, A. E. & Ibrahim, A. Development of HPLC method for determination of Sitagliptin in human plasma using fluorescence detector by experimental design approach. J. Anal. Chem. Lett. 8(6), 813\u2013828. https:\/\/doi.org\/10.1080\/22297928.2018.1545603 (2018).","journal-title":"J. Anal. Chem. Lett."},{"key":"53178_CR31","unstructured":"Qassas, M. K., Ameral-mardini, M. & Ghazal, H. J. I. A validated HPLC stability indicating method for the determination of sitagliptin in bulk drug substance and tablets. Int. J. Pharm. Sci. Rev. Res., 32(1), (2015). 33,194\u2009\u2013\u2009119."},{"issue":"5","key":"53178_CR32","first-page":"407","volume":"76","author":"P Ramalingam","year":"2014","unstructured":"Ramalingam, P., Bhaskar, V. U., Reddy, Y. P. & Kumar, K. V. J. I. Stability-indicating RP-HPLC method for the simultaneous determination of Sitagliptin and Simvastatin in tablets. Indian J. Pharm. Sci. 76(5), 407 (2014).","journal-title":"Indian J. Pharm. Sci."},{"issue":"10","key":"53178_CR33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2298\/JSC141227046R","volume":"80","author":"R Rezaee","year":"2015","unstructured":"Rezaee, R., Qomi, M. & Piroozi, F. J. Hollow-fiber micro-extraction combined with HPLC for the determination of Sitagliptin in urine samples. J. Serb. Chem. Soc. 80(10), 1311\u20131320. https:\/\/doi.org\/10.2298\/JSC141227046R (2015).","journal-title":"J. Serb. Chem. Soc."},{"issue":"9","key":"53178_CR34","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.13040\/IJPSR.0975-8232.4(9).3494-03","volume":"4","author":"DP Sonune","year":"2013","unstructured":"Sonune, D. P. & Mone, M. K. J. I. Isolation, characterization of degradation products of Sitagliptin and development of validated stability-indicating HPLC assay method for Sitagliptin API and tablets. Int. J. Pharm. Sci. Res. 4(9), 3494\u20133503. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.4(9).3494-03 (2013).","journal-title":"Int. J. Pharm. Sci. Res."},{"issue":"7","key":"53178_CR35","first-page":"702","volume":"2","author":"N Disha","year":"2015","unstructured":"Disha, N. & Gurupadhayya, B. J. I. Spectrophotometric determination of Sitagliptin phosphate in bulk and pharmaceutical formulations. IJISET 2(7), 702\u2013709 (2015).","journal-title":"IJISET"},{"issue":"3","key":"53178_CR36","first-page":"871","volume":"4","author":"P Pathade","year":"2011","unstructured":"Pathade, P., Imran, M., Bairagi, V. & Ahire, Y. J. Development and validation of stability indicating UV spectrophotometric method for the estimation of Sitagliptin phosphate in bulk and tablet dosage form. J. Pharm. Res. 4(3), 871\u2013873 (2011).","journal-title":"J. Pharm. Res."},{"issue":"4","key":"53178_CR37","first-page":"194","volume":"3","author":"J Pritam","year":"2011","unstructured":"Pritam, J. et al. Development and validation of first order derivative UV-spectrophotometric method for determination of Sitagliptin in bulk and in formulation. IJDDR 3(4), 194\u2013199 (2011).","journal-title":"IJDDR"},{"key":"53178_CR38","first-page":"254","volume":"7","author":"P Ravisankar","year":"2014","unstructured":"Ravisankar, P., Mounika, G., Devadasu, C. & DevalaRao, G. J. A simple validated UV spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form. J. Chem. Pharmaceut Sci. 7, 254 (2014).","journal-title":"J. Chem. Pharmaceut Sci."},{"key":"53178_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1590\/S0100-46702010000300003","volume":"35","author":"CB Sekaran","year":"2010","unstructured":"Sekaran, C. B. & Rani, A. P. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor, sitagliptin, in its pharmaceutical preparations. Eclet. Quim. 35, 45\u201353. https:\/\/doi.org\/10.1590\/S0100-46702010000300003 (2010).","journal-title":"Eclet. Quim."},{"issue":"1","key":"53178_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/bio.70404","volume":"41","author":"TZ Attia","year":"2026","unstructured":"Attia, T. Z., Shahin, R. Y., Taha, H. M. & Noureldeen, D. A. Simple and novel fluorimetric protocol for sitagliptin estimation through sensitivity enhancement using acetic acid: Application to pharmaceutical dosage form with green assessment. J. Lumin. 41(1), e70404. https:\/\/doi.org\/10.1002\/bio.70404 (2026).","journal-title":"J. Lumin."},{"issue":"5","key":"53178_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1573412913666170906164249","volume":"14","author":"MF Bakr Ali","year":"2018","unstructured":"Bakr Ali, M. F. & Atia, N. N. Sensitive spectrofluorimetric methods for determination of sitagliptin phosphate, dipeptidyl peptidase-4 inhibitor, in pharmaceutical tablets and spiked human urine. Curr. Pharm. Anal. 14(5), 483\u2013490. https:\/\/doi.org\/10.2174\/1573412913666170906164249 (2018).","journal-title":"Curr. Pharm. Anal."},{"issue":"3","key":"53178_CR42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/157341212801619270","volume":"8","author":"S Caglar","year":"2012","unstructured":"Caglar, S., Onal, A. & Toker, S. Determination of sitagliptin with fluorescamine in tablets and spiked serum samples by spectrofluorimetry and a degradation study. Curr. Pharm. Anal. 8(3), 278\u2013285. https:\/\/doi.org\/10.2174\/157341212801619270 (2012).","journal-title":"Curr. Pharm. Anal."},{"issue":"6","key":"53178_CR43","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/bio.4502","volume":"38","author":"MA El Hamd","year":"2023","unstructured":"El Hamd, M. A., Soltan, O. M., Abdelrahman, K. S., Alsaggaf, W. T. & Abu-hassan, A. A. A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: Application to dosage forms and biological fluid evaluation. J. Lumin. 38(6), 744\u2013752. https:\/\/doi.org\/10.1002\/bio.4502 (2023).","journal-title":"J. Lumin."},{"key":"53178_CR44","doi-asserted-by":"publisher","DOI":"10.31838\/ijpr\/2020.SP1.269.(","author":"AJ Saleem","year":"2020","unstructured":"Saleem, A. J., Al-Awadie, N. S. & J. I. New developed method for determination and detecting of Sitagliptin Phosphate via the use of ISNAG\u2013fluorimeter instrument. Int. J. Pharm. Res. https:\/\/doi.org\/10.31838\/ijpr\/2020.SP1.269.( (2020).","journal-title":"Int. J. Pharm. Res."},{"issue":"8","key":"53178_CR45","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1007\/s11696-021-01646-3","volume":"75","author":"MM Elhassan","year":"2021","unstructured":"Elhassan, M. M., Mahmoud, A. M., Hegazy, M. A. & Mowaka, S. In-line monitoring of sitagliptin dissolution profile from tablets utilizing an eco-friendly potentiometric sensor. Chem. Pap. 75(8), 4165\u20134176. https:\/\/doi.org\/10.1007\/s11696-021-01646-3 (2021).","journal-title":"Chem. Pap."},{"issue":"13","key":"53178_CR46","doi-asserted-by":"publisher","DOI":"10.1149\/1945-7111\/abbb43","volume":"167","author":"A G\u00f3rska","year":"2020","unstructured":"G\u00f3rska, A., Paczosa-Bator, B. & Piech, R. J. Highly sensitive adsorptive stripping voltammetric method for sitagliptin determination on renewable amalgam film electrode. J. Electrochem. Soc. 167(13), 136510. https:\/\/doi.org\/10.1149\/1945-7111\/abbb43 (2020).","journal-title":"J. Electrochem. Soc."},{"issue":"14","key":"53178_CR47","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1039\/D1NA00194A","volume":"3","author":"I Haq","year":"2021","unstructured":"Haq, I. et al. Determination of sitagliptin in human plasma using a smart electrochemical sensor based on electroactive molecularly imprinted nanoparticles. J. Nanoscale Adv. 3(14), 4276\u20134285. https:\/\/doi.org\/10.1039\/D1NA00194A (2021).","journal-title":"J. Nanoscale Adv."},{"issue":"3","key":"53178_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.69613\/z7svx946","volume":"3","author":"SA Ahmed","year":"2025","unstructured":"Ahmed, S. A. & Puri, H. K. J. Development and validation of a rapid RP-HPLC method for simultaneous estimation of empagliflozin and sitagliptin phosphate in pharmaceutical formulations. JOPIR 3(3), 286\u2013294. https:\/\/doi.org\/10.69613\/z7svx946 (2025).","journal-title":"JOPIR"},{"issue":"8","key":"53178_CR49","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.52711\/0974-360X.2023.00612","volume":"16","author":"A Dwivedi","year":"2023","unstructured":"Dwivedi, A. & Sharma, R. J. R. Development and validation of simultaneous equation method for estimation of sitagliptin phosphate and empagliflozin in bulk form by UV spectroscopy. RJPT 16(8), 3714\u20133718. https:\/\/doi.org\/10.52711\/0974-360X.2023.00612 (2023).","journal-title":"RJPT"},{"issue":"1","key":"53178_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99718-x","volume":"15","author":"HH Abuseada","year":"2025","unstructured":"Abuseada, H. H., Abdel Sattar, O. I., Madkour, A. W. & Taha, A. S. Ecofriendly first-derivative synchronous fluorometric method for simultaneous determination of atorvastatin and aspirin in pharmaceutical preparations. J. Sci Rep 15(1), 17787. https:\/\/doi.org\/10.1038\/s41598-025-99718-x (2025).","journal-title":"J. Sci Rep"},{"issue":"43","key":"53178_CR51","doi-asserted-by":"publisher","first-page":"18679","DOI":"10.1039\/D0NJ03636F","volume":"44","author":"KA Attia","year":"2020","unstructured":"Attia, K. A. et al. Development and validation of a highly sensitive second derivative synchronous fluorescence spectroscopic method for the simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation and human plasma. New J. Chem. 44(43), 18679\u201318685. https:\/\/doi.org\/10.1039\/D0NJ03636F (2020).","journal-title":"New J. Chem."},{"issue":"2","key":"53178_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/bio.4641","volume":"39","author":"HA Batakoushy","year":"2024","unstructured":"Batakoushy, H. A. et al. A novel sustainable second-derivative synchronous spectrofluorimetric method for the simultaneous determination of olmesartan medoxomil and rosuvastatin calcium in bulk and formulations: Integrated greenness and whiteness evaluation. J. Lumin. 39(2), e4641. https:\/\/doi.org\/10.1002\/bio.4641 (2024).","journal-title":"J. Lumin."},{"issue":"4","key":"53178_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/bio.2764","volume":"30","author":"F Ibrahim","year":"2015","unstructured":"Ibrahim, F., El-Enany, N., El\u2010Shaheny, R. & Mikhail, I. E. Simultaneous determination of desloratadine and montelukast sodium using second\u2010derivative synchronous fluorescence spectrometry enhanced by an organized medium with applications to tablets and human plasma. J. Lumin. 30(4), 485\u2013494. https:\/\/doi.org\/10.1002\/bio.2764 (2015).","journal-title":"J. Lumin."},{"key":"53178_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122955","volume":"1184","author":"MF Kamal","year":"2021","unstructured":"Kamal, M. F., Morshedy, S., Saad, D. A. & Moneeb, M. S. J. Second-derivative synchronous fluorimetry and time-programmed HPLC-fluorescence detection for simultaneous estimation of flibanserin and sitagliptin phosphate in synthetic mixtures and human plasma samples. J. Chromatogr. A 1184, 122955. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122955 (2021).","journal-title":"J. Chromatogr. A"},{"issue":"8","key":"53178_CR55","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1007\/s10895-024-04064-2","volume":"35","author":"AS Radwan","year":"2025","unstructured":"Radwan, A. S. et al. A. I. J. A Novel Ultrasensitive Second Derivative Synchronous Spectrofluorimetric Approach for the Simultaneous Analysis of the Co-Administered Antihypertensives, Telmisartan and Carvedilol in Biological Fluids and Tablets: Greenness and Blueness Assessment. J. Fluoresc. 35 (8), 7085\u20137098. https:\/\/doi.org\/10.1007\/s10895-024-04064-2 (2025).","journal-title":"J. Fluoresc"},{"issue":"1","key":"53178_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13065-022-00855-5","volume":"16","author":"S Ramzy","year":"2022","unstructured":"Ramzy, S., Abdelazim, A. H. & Hasan, M. A. Application of green first derivative synchronous spectrofluorometric method for quantitative analysis of fexofenadine hydrochloride and pseudoephedrine hydrochloride in pharmaceutical preparation and spiked human plasma. J. BMC Chem. 16 (1), 62. https:\/\/doi.org\/10.1186\/s13065-022-00855-5 (2022).","journal-title":"J. BMC Chem."},{"issue":"1","key":"53178_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10895-007-0238-5","volume":"18","author":"M Walash","year":"2008","unstructured":"Walash, M., Belal, F., El-Enany, N. & Abdelal, A. J. Second-derivative synchronous fluorometric method for the simultaneous determination of cinnarizine and domperidone in pharmaceutical preparations. Application to biological fluids. J. Fluoresc. 18(1), 61\u201374. https:\/\/doi.org\/10.1007\/s10895-007-0238-5 (2008).","journal-title":"J. Fluoresc."},{"key":"53178_CR58","unstructured":"Guideline, I. H. T. Validation of analytical procedures: text and methodology. 1(20), 05. (2005)."},{"key":"53178_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2022.116553","volume":"149","author":"W Wojnowski","year":"2022","unstructured":"Wojnowski, W., Tobiszewski, M., Pena-Pereira, F. & Psillakis, E. AGREEprep\u2013analytical greenness metric for sample preparation. TrAC, Trends Anal. Chem. 149, 116553. https:\/\/doi.org\/10.1016\/j.trac.2022.116553 (2022).","journal-title":"TrAC, Trends Anal. Chem."},{"issue":"15","key":"53178_CR60","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1039\/C6AY00478D","volume":"8","author":"M Tobiszewski","year":"2016","unstructured":"Tobiszewski, M. Metrics for green analytical chemistry. J. Anal. Methods. 8(15), 2993\u20132999. https:\/\/doi.org\/10.1039\/C6AY00478D (2016).","journal-title":"J. Anal. Methods."},{"key":"53178_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.greeac.2024.100126","volume":"10","author":"FR Mansour","year":"2024","unstructured":"Mansour, F. R., Omer, K. M. & P\u0142otka-Wasylka, J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. J. Green Anal. Chem. 10, 100126. https:\/\/doi.org\/10.1016\/j.greeac.2024.100126 (2024).","journal-title":"J. Green Anal. Chem."},{"key":"53178_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka, A., Migaszewski, Z. M., Konieczka, P. & Namie\u015bnik, J. Analytical eco-scale for assessing the greenness of analytical procedures. J. TrAC 37, 61\u201372. https:\/\/doi.org\/10.1016\/j.trac.2012.03.013 (2012).","journal-title":"J. TrAC"},{"issue":"1","key":"53178_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-025-01486-2","volume":"19","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R. & Nowak, P. M. Introducing the carbon footprint reduction index (CaFRI) as a software-supported tool for greener laboratories in chemical analysis. BMC Chem. 19(1), 121. https:\/\/doi.org\/10.1186\/s13065-025-01486-2 (2025).","journal-title":"BMC Chem."},{"issue":"16","key":"53178_CR64","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","volume":"91","author":"PM Nowak","year":"2019","unstructured":"Nowak, P. M. & Ko\u015bcielniak, P. What color is your method? Adaptation of the RGB additive color model to analytical method evaluation. J. Anal. Chem. 91(16), 10343\u201310352. https:\/\/doi.org\/10.1021\/acs.analchem.9b01872 (2019).","journal-title":"J. Anal. Chem."},{"key":"53178_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2021.116223","volume":"138","author":"PM Nowak","year":"2021","unstructured":"Nowak, P. M., Wietecha-Pos\u0142uszny, R. & Pawliszyn, J. White analytical chemistry: An approach to reconcile the principles of green analytical chemistry and functionality. TrAC Trends Anal. Chem. 138, 116223. https:\/\/doi.org\/10.1016\/j.trac.2021.116223 (2021).","journal-title":"TrAC Trends Anal. Chem."},{"issue":"19","key":"53178_CR66","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. Blue applicability grade index (BAGI) and software: A new tool for the evaluation of method practicality. Green Chem. 25(19), 7598\u20137604. https:\/\/doi.org\/10.1039\/D3GC02347H (2023).","journal-title":"Green Chem."},{"key":"53178_CR67","doi-asserted-by":"crossref","unstructured":"Moreton, R. C. J. I. United States pharmacopeia-national formulary. IJPE, 6(3). (2016).","DOI":"10.66617\/001c.925"},{"issue":"10","key":"53178_CR68","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12325-012-0055-3","volume":"29","author":"T Brand","year":"2012","unstructured":"Brand, T., Macha, S., Mattheus, M., Pinnetti, S. & Woerle, H. J. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv. Ther. 29(10), 889\u2013899. https:\/\/doi.org\/10.1007\/s12325-012-0055-3 (2012).","journal-title":"Adv. Ther."},{"issue":"7","key":"53178_CR69","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","volume":"54","author":"AJ Scheen","year":"2015","unstructured":"Scheen, A. J. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin. Pharmacokinet. 54(7), 691\u2013708. https:\/\/doi.org\/10.1007\/s40262-015-0264-4 (2015).","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"53178_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen, A. J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53(3), 213\u2013225. https:\/\/doi.org\/10.1007\/s40262-013-0126-x (2014).","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"53178_CR71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1039\/D0AY02169E","volume":"13","author":"M Gamal","year":"2021","unstructured":"Gamal, M., Naguib, I. A., Panda, D. S. & Abdallah, F. F. Comparative study of four greenness assessment tools for selection of greenest analytical method for assay of hyoscine N-butyl bromide. Anal. Methods 13(3), 369\u2013380. https:\/\/doi.org\/10.1039\/D0AY02169E (2021).","journal-title":"Anal. Methods"},{"key":"53178_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.teac.2023.e00202","volume":"38","author":"MS Imam","year":"2023","unstructured":"Imam, M. S. & Abdelrahman, M. M. How environmentally friendly is the analytical process? A paradigm overview of ten greenness assessment metric approaches for analytical methods. Trends Environ. Anal. Chem. 38, e00202. https:\/\/doi.org\/10.1016\/j.teac.2023.e00202 (2023).","journal-title":"Trends Environ. Anal. Chem."},{"key":"53178_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2023.117196","volume":"166","author":"LP Kowtharapu","year":"2023","unstructured":"Kowtharapu, L. P., Katari, N. K., Muchakayala, S. K. & Marisetti, V. M. Green metric tools for analytical methods assessment critical review, case studies and crucify. TrAC Trends Anal. Chem. 166, 117196. https:\/\/doi.org\/10.1016\/j.trac.2023.117196 (2023).","journal-title":"TrAC Trends Anal. Chem."},{"issue":"21","key":"53178_CR74","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1039\/d1gc02318g","volume":"23","author":"J P\u0142otka-Wasylka","year":"2021","unstructured":"P\u0142otka-Wasylka, J. & Wojnowski, W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 23(21), 8657\u20138665. https:\/\/doi.org\/10.1039\/d1gc02318g (2021).","journal-title":"Green Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53178-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53178-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:18:26Z","timestamp":1779257906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53178-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53178"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53178-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15708"}}